Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

What Renflexis Pricing Says About Medicare's Biosimilars Policy

Jul 28 2017

• By Cathy Kelly

Syringes stuck in a dartboard

Related Content

Biosimilars Payments In Medicare: CMS Signals Willingness To Change

Jul 17 2017

Merck's Second-To-Market Renflexis Biosimilar Priced Below The First

Jul 24 2017

Related Companies

Merck & Co., Inc.

Pfizer Inc.

Johnson & Johnson

Additional Topics

United States Biosimilars Pricing Strategies Policy BioPharmaceutical

More from Biosimilars

More from Biosimilars & Generics

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window